Coherus BioSciences (CHRS) Reports Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira Biosimilar Candidate)
Tweet Send to a Friend
Coherus BioSciences, Inc. (NASDAQ: CHRS), today reported topline results from the first of three ongoing pharmacokinetic bioequivalence (“PK/BE”) studies comparing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
